Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW

Japan on March 5 announced new NHI prices for listed medicines, effective April 1, revealing a 37.3% slash for Novartis Pharma’s Xolair (omalizumab) after its label expansion into pollen allergy, and a further 20.9% reduction for MSD’s fast-growing blockbuster Keytruda...read more